PARP inhibitor response prediction using PET scan and blood test in metastatic prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial uses a special PET scan and a blood test to see if a PARP inhibitor (a type of targeted therapy) will work for metastatic prostate cancer. It aims to predict treatment response early so you can get the best care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a man aged 18 or older.
- You must have metastatic prostate cancer that has spread and is resistant to hormone therapy (mCRPC).
- You must have a specific gene change (like BRCA, ATM, or similar) that makes PARP inhibitors likely to work.
- You must be scheduled to start a PARP inhibitor as part of your regular care.
- You must have a tumor that is at least 1 cm across on a scan, or clearly visible on another imaging test.
- You must be on ongoing hormone therapy with low testosterone levels, or have had your testicles removed.
- Your PSA level must be 2 or higher.
- You must be able to lie still for about 30 minutes for the PET scan.
- You cannot have had PARP inhibitor treatment before.
- You must not have another active cancer (except for non-melanoma skin cancer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, talazoparib and enzalutamide, in men with advanced prostate cancer that has progressed after previous treatment with a hormone therapy called an AR inhibitor. It aims to see if this combination can help control the cancer and delay further progression.
This trial tests whether adding a new drug (saruparib) to standard radiation and hormone therapy can help prevent prostate cancer from spreading to other parts of the body. It is for men with high-risk prostate cancer that has a BRCA gene mutation.
This study is testing a new blood test that looks for cancer cells in your blood and checks if your tumor has a specific feature linked to DNA repair. The goal is to see if this blood test can help guide whether PARP inhibitor medicines—which target cancers with this feature—might work for you.
This trial uses a special PET scan (POSLUMA) before and after radiation to see if it helps treat prostate cancer that has spread to a few spots outside the pelvis. It's for men whose cancer still responds to hormone therapy and who have not had widespread spread.
This study looks at how well two different PSMA PET scans work for men with advanced prostate cancer. The scans help doctors see where the cancer is, which can guide treatment decisions and help you and your doctor plan next steps.
This trial tests whether doing a second PET scan during treatment can help doctors decide if more precise radiation (SABR) should be used on all cancer spots in men with prostate cancer that has spread. It aims to see if this approach can better control the cancer while reducing side effects.
Hear when a new Metastatic Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.